Worldwide curiosity spiked when news broke about Jeff Bezos’s three-day wedding in Venice. The price tag dwarfs even the best ...

WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the ...

Vanda sues FDA over hearing delay as agency points to mass layoffs, other litigation with the biopharma By Gabrielle Masson Apr 23, 2025 10:33am Vanda Pharmaceuticals FDA CDER Complete Response Letter ...

If you grew up in Singapore, chances are you've seen the Vanda Miss Joaquim on school worksheets, stamps, coins… or maybe even growing at your grandma's house. But did you know that our beloved ...

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a small company with a strong revenue figure and more cash than its market cap, yet it has been trading sideways for a long time now. I haven’t ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), currently valued at $273.5 million, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bysanti ...

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of ...

Vanda has projected its 2025 revenue to range between $210 million and $250 million, indicating a potential growth trajectory. 3rd party Ad. Not an offer or recommendation by Investing.com.

Vanda coerulea and its hybrids make up about one-third of orchids in floral display at Gardens by the Bay. Read more at straitstimes.com. Read more at straitstimes.com.

Under the terms of the agreement, Vanda will make to Anaptys an upfront payment of $10 million and a $5 million payment for existing drug supply. Anaptys is also eligible to receive up to $35 million ...

Vanda Pharmaceuticals Inc. By Sara Gilgore – Staff Reporter, Washington Business Journal Jan 27, 2025 Preview this article 1 min ...

FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide ...